Successful management of choroidal metastasis with intravitreal ranibizumab injections

Uveal metastases are the most frequent intraocular malignancy in adults. Among various treatment modalities, previous studies have described intravitreal injections of bevacizumab to suppress tumor vascularity. Because of its smaller molecular size, compared to bevacizumab, ranibizumab may offer better tissue penetration and be more efficient in suppressing neovascularization in choroidal lesions. This report presents two cases of choroidal metastases from bronchial and nasopharyngeal carcinoma that were treated as a series of three intravitreal ranibizumab injections (0.5 mg each), showing definite signs of regression. The encouraging results imply that intravitreal ranibizumab may be effective in the management of choroidal metastases, but this finding will have to be confirmed by larger prospective studies.